Aptose Biosciences IncNASDAQ:APTONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)View on Canadian Exchange
- LAST PRICE0.5680
- TODAY'S CHANGE (%)-0.0004 (-0.0704%)
- Bid / Lots0.5700/ 20
- Ask / Lots0.5849/ 1
- Open / Previous Close0.5991 / 0.5684
- Day Range
- 52 Week Range
- Volume95,391
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APTO |
|---|---|---|
| 09:32 ET | 1507 | 0.591 |
| 09:34 ET | 800 | 0.59 |
| 09:36 ET | 620 | 0.59 |
| 09:38 ET | 200 | 0.59 |
| 09:39 ET | 2050 | 0.5974 |
| 09:41 ET | 500 | 0.592 |
| 09:43 ET | 1800 | 0.5998 |
| 09:45 ET | 2000 | 0.5999 |
| 09:48 ET | 1800 | 0.599899 |
| 09:50 ET | 700 | 0.592 |
| 09:52 ET | 2100 | 0.592 |
| 09:54 ET | 100 | 0.591 |
| 09:56 ET | 200 | 0.592 |
| 09:57 ET | 480 | 0.5999 |
| 09:59 ET | 200 | 0.59 |
| 10:03 ET | 100 | 0.59 |
| 10:06 ET | 1075 | 0.59 |
| 10:08 ET | 100 | 0.581 |
| 10:10 ET | 350 | 0.576 |
| 10:12 ET | 200 | 0.576 |
| 10:14 ET | 100 | 0.576 |
| 10:17 ET | 200 | 0.567 |
| 10:19 ET | 100 | 0.567 |
| 10:21 ET | 560 | 0.59 |
| 10:24 ET | 595 | 0.5672 |
| 10:26 ET | 338 | 0.567 |
| 10:28 ET | 100 | 0.57 |
| 10:30 ET | 200 | 0.567 |
| 10:32 ET | 200 | 0.567 |
| 10:33 ET | 200 | 0.565 |
| 10:35 ET | 200 | 0.565 |
| 10:37 ET | 500 | 0.5652 |
| 10:39 ET | 700 | 0.5667 |
| 10:42 ET | 200 | 0.5601 |
| 10:44 ET | 300 | 0.562 |
| 10:46 ET | 5800 | 0.5651 |
| 10:48 ET | 700 | 0.5682 |
| 10:50 ET | 850 | 0.5641 |
| 10:51 ET | 4990 | 0.58 |
| 10:53 ET | 3825 | 0.59 |
| 10:55 ET | 750 | 0.588811 |
| 10:57 ET | 5200 | 0.5889 |
| 11:08 ET | 100 | 0.58 |
| 11:09 ET | 362 | 0.58 |
| 11:11 ET | 200 | 0.561 |
| 11:13 ET | 100 | 0.561 |
| 11:15 ET | 200 | 0.562 |
| 11:18 ET | 200 | 0.562 |
| 11:20 ET | 100 | 0.561 |
| 11:22 ET | 300 | 0.57 |
| 11:24 ET | 200 | 0.561 |
| 11:26 ET | 200 | 0.561 |
| 11:27 ET | 530 | 0.5608 |
| 11:29 ET | 100 | 0.5608 |
| 11:31 ET | 100 | 0.5608 |
| 11:33 ET | 1000 | 0.5654 |
| 11:36 ET | 100 | 0.5661 |
| 11:38 ET | 100 | 0.5661 |
| 11:40 ET | 200 | 0.5661 |
| 11:42 ET | 100 | 0.561 |
| 11:45 ET | 100 | 0.5608 |
| 11:47 ET | 100 | 0.56 |
| 11:51 ET | 100 | 0.56 |
| 11:54 ET | 100 | 0.56 |
| 11:58 ET | 100 | 0.56 |
| 12:02 ET | 100 | 0.56 |
| 12:03 ET | 100 | 0.56 |
| 12:05 ET | 100 | 0.56 |
| 12:07 ET | 100 | 0.56 |
| 12:09 ET | 251 | 0.5601 |
| 12:14 ET | 100 | 0.56 |
| 12:18 ET | 200 | 0.56 |
| 12:20 ET | 100 | 0.56 |
| 12:21 ET | 100 | 0.56 |
| 12:23 ET | 100 | 0.56 |
| 12:25 ET | 100 | 0.56 |
| 12:27 ET | 100 | 0.56 |
| 12:30 ET | 100 | 0.56 |
| 12:32 ET | 100 | 0.56 |
| 12:34 ET | 100 | 0.56 |
| 12:36 ET | 100 | 0.56 |
| 12:39 ET | 100 | 0.56 |
| 12:41 ET | 100 | 0.56 |
| 12:43 ET | 100 | 0.56 |
| 12:45 ET | 100 | 0.56 |
| 12:48 ET | 200 | 0.56 |
| 12:50 ET | 100 | 0.56 |
| 12:52 ET | 200 | 0.56 |
| 12:54 ET | 481 | 0.56 |
| 12:56 ET | 100 | 0.56 |
| 12:57 ET | 530 | 0.5594 |
| 12:59 ET | 100 | 0.555 |
| 01:01 ET | 200 | 0.552 |
| 01:03 ET | 100 | 0.552 |
| 01:06 ET | 100 | 0.552 |
| 01:10 ET | 200 | 0.552 |
| 01:12 ET | 100 | 0.552 |
| 01:15 ET | 200 | 0.552 |
| 01:17 ET | 100 | 0.552 |
| 01:19 ET | 100 | 0.552 |
| 01:21 ET | 200 | 0.552 |
| 01:24 ET | 212 | 0.5603 |
| 01:26 ET | 200 | 0.552 |
| 01:28 ET | 100 | 0.552 |
| 01:30 ET | 300 | 0.552 |
| 01:32 ET | 635 | 0.552 |
| 01:33 ET | 100 | 0.552 |
| 01:35 ET | 100 | 0.552 |
| 01:37 ET | 100 | 0.552 |
| 01:39 ET | 200 | 0.552 |
| 01:42 ET | 100 | 0.552 |
| 01:44 ET | 100 | 0.552 |
| 01:50 ET | 100 | 0.5525 |
| 01:51 ET | 100 | 0.5525 |
| 01:53 ET | 100 | 0.5525 |
| 01:55 ET | 100 | 0.5525 |
| 01:57 ET | 100 | 0.5525 |
| 02:00 ET | 100 | 0.5525 |
| 02:02 ET | 100 | 0.5525 |
| 02:04 ET | 200 | 0.5525 |
| 02:06 ET | 100 | 0.5525 |
| 02:08 ET | 100 | 0.5525 |
| 02:09 ET | 100 | 0.5525 |
| 02:11 ET | 400 | 0.5611 |
| 02:15 ET | 110 | 0.561 |
| 02:18 ET | 100 | 0.5525 |
| 02:20 ET | 100 | 0.5525 |
| 02:22 ET | 100 | 0.5525 |
| 02:26 ET | 100 | 0.5525 |
| 02:29 ET | 100 | 0.5525 |
| 02:31 ET | 100 | 0.5525 |
| 02:33 ET | 100 | 0.5525 |
| 02:38 ET | 100 | 0.5525 |
| 02:40 ET | 2053 | 0.5695 |
| 02:42 ET | 7508 | 0.5675 |
| 02:44 ET | 1276 | 0.5665 |
| 02:45 ET | 500 | 0.5655 |
| 02:49 ET | 100 | 0.552 |
| 02:51 ET | 200 | 0.553 |
| 02:54 ET | 200 | 0.552 |
| 02:56 ET | 100 | 0.552 |
| 02:58 ET | 200 | 0.552 |
| 03:00 ET | 200 | 0.552 |
| 03:02 ET | 200 | 0.552 |
| 03:03 ET | 100 | 0.552 |
| 03:05 ET | 200 | 0.552 |
| 03:07 ET | 100 | 0.552 |
| 03:09 ET | 4374 | 0.5501 |
| 03:12 ET | 100 | 0.55 |
| 03:14 ET | 200 | 0.55 |
| 03:16 ET | 100 | 0.55 |
| 03:18 ET | 200 | 0.55 |
| 03:20 ET | 300 | 0.567 |
| 03:21 ET | 200 | 0.551 |
| 03:23 ET | 200 | 0.553 |
| 03:25 ET | 200 | 0.553 |
| 03:27 ET | 300 | 0.56 |
| 03:30 ET | 100 | 0.553 |
| 03:32 ET | 100 | 0.553 |
| 03:34 ET | 200 | 0.553 |
| 03:36 ET | 100 | 0.553 |
| 03:38 ET | 200 | 0.553 |
| 03:39 ET | 100 | 0.552 |
| 03:43 ET | 383 | 0.552 |
| 03:45 ET | 2640 | 0.553 |
| 03:48 ET | 460 | 0.552 |
| 03:50 ET | 300 | 0.552 |
| 03:52 ET | 300 | 0.552 |
| 03:54 ET | 300 | 0.552 |
| 03:56 ET | 200 | 0.552 |
| 03:57 ET | 300 | 0.5525 |
| 03:59 ET | 300 | 0.568 |
Jul 19, 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq, from 5:00PM ET on Friday Jul 19, 2024 by Dow Jones
5:00PM ET on Friday Jul 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aptose Biosciences Inc | 10.3M | -0.1x | --- |
Cell MedX Corp | 10.4M | -12.1x | --- |
Alterity Therapeutics Ltd | 15.8M | -0.8x | --- |
CeCors Inc | 10.0M | 0.0x | --- |
Cardio Diagnostics Holdings Inc | 10.6M | -0.6x | --- |
NuCana PLC | 7.6M | 0.0x | --- |
Company Information
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.
Contact Information
- Headquarters
- 251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3
- Phone
- 647-479-9828
- Fax
- 416-798-2200
Executives
- Chairman of the Board, President, Chief Executive Officer
- William Rice
- Chief Financial Officer, Senior Vice President, Company Secretary, Chief Business Officer
- Fletcher Payne
- Senior Vice President, Chief Medical Officer
- Rafael Bejar
- Lead Independent Director
- Denis Burger
- Independent Director
- Carol Ashe
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-6.29 |
Book Value | $-0.37 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
